Drugs & Therapy Perspectives

, Volume 35, Issue 2, pp 77–85 | Cite as

A systematic review of second-line controller combination therapy options for the management of asthma

  • Muhasaparur Ganesan RajanandhEmail author
  • Sivaguru Paramesh Ahalya
  • Rajendran Anjali
  • Arunagiri Abirami
  • Jamindar Ganesh Bhuvaneswari
Review Article



First-line controller combination therapy for the management of asthma is a low-dose inhaled corticosteroid (LD-ICS) + a long-acting β-agonist (LABA), and second-line options are a LD-ICS + a leukotriene receptor antagonist (LTRA), LD-ICS + sustained-release theophylline (SR-T), and a medium-/high-dose ICS (HD-ICS).


The purpose of this review is to assess the various second-line combination therapy options for the management of asthma.


We systematically reviewed randomized controlled trials (RCTs) in adult patients with asthma, extracting and synthesizing data from eligible articles on study design, duration, randomization, blinding, withdrawal, run-in period, type of analysis, and names and doses of drugs. The primary outcome measure was change in percentage predicted forced expiratory volume in 1 second (% FEV1), and the secondary outcome was frequency of asthma exacerbations.


Nine RCTs (three blinded and six open-label trials) were selected for the review. One study investigated LD-ICS + LTRA compared with HD-ICS, two studies investigated LD-ICS + SR-T compared with HD-ICS, and five studies investigated LD-ICS + LTRA compared with LD-ICS + SR-T. Only one of the nine RCTs compared all treatment options as mentioned in Global Initiative for Asthma (GINA) guidelines. Seven RCTs examined the primary outcome (change in % FEV1). No significant difference was observed (four RCTs; % FEV1) between LD-ICS + LTRA and LD-ICS + SR-T, but one RCT reported better clinical improvement with LD-ICS + LTRA than with LD-ICS + SR-T (% FEV1). Likewise, similar clinical effects (two RCTs) were observed between LD-ICS + SR-T and HD-ICS, one based on % FEV1 and the other based on exacerbation improvement. One RCT concluded that LD-ICS + LTRA was an effective and well-tolerated alternative to HD-ICS (exacerbation improvement). LD-ICS + LTRA resulted in greater clinical improvement when comparing all second-line treatment options in one RCT (% FEV1 and exacerbation improvement). All nine studies had a high risk of bias according to a modified Cochrane risk-of-bias tool for quality assessment of RCTs.


Existing RCTs provide low-quality evidence of the superiority of second-line controller options for asthma management. This systematic review recommends that clinically relevant, stringently designed RCTs with appropriate sample sizes and durations are conducted to identify the best second-line controller option.


Compliance with ethical standards

Conflict of interest

MGR, SPA, RA, AA, JGB have no conflicts of interest that are directly relevant to the content of this article.


No sources of funding were used to conduct this study or prepare this manuscript.


  1. 1.
    Rajanandh MG. An overview and update on asthma and its management. J Med Sci. 2015;15:122–9.CrossRefGoogle Scholar
  2. 2.
    Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ. 2003;326(7390):621.CrossRefGoogle Scholar
  3. 3.
    Rajanandh MG, Nageswari AD, Irshad PP, et al. Dose-reduction of inhaled corticosteroids with the addition of leukotriene antagonist is clinical significance in asthma patients? A randomized clinical trial. World Appl Sci J. 2013;24:276–81.Google Scholar
  4. 4.
    Ilango K, Rajanaandh MG, Nageswari AD. Roflumilast, an upcoming drug for curing asthma and COPD. Int J Pharm Res Tech. 2013;5:130–5.Google Scholar
  5. 5.
    Virchow JC, Prasse JR, Naya A, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000;162:578–85.CrossRefGoogle Scholar
  6. 6.
    Rajanandh MG, Nageswari AD, Ilango K. Importance of pharmacist provided patient education on knowledge, attitude, practice and quality of life in asthma patients in a South Indian hospital. J Med Sci. 2014;14:254–60.CrossRefGoogle Scholar
  7. 7.
    Castro-Rodriguez C, Rodrigo GJ. A systematic review of long acting β2 agonists versus higher doses of inhaled corticosteroids in asthma. Pediatrics. 2012;130(3):e650–7.CrossRefGoogle Scholar
  8. 8.
    Rai SP, Patil AP, Vardhan V, et al. Best treatment guidelines for bronchial asthma. Med J Armed Forces India. 2007;63(3):264–8.CrossRefGoogle Scholar
  9. 9.
    Fanta CH. Asthma. N Engl J Med. 2009;360(11):1002–14.CrossRefGoogle Scholar
  10. 10.
    Rajanandh MG, Nageswari AD, Ilango K. Influence of demographic status on pulmonary function, quality of life and symptom scores in patients with mild to moderate persistant asthma. J Exp Clin Med. 2014;6:102–4.CrossRefGoogle Scholar
  11. 11.
    Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Update 2012. Accessed 16 Sept 2011.
  12. 12.
    Aggarwal AN, Chaudhry K, Chhabra SK, et al. Prevalance and risk factors for Bronchial asthma in Indian adults: a multicentre study. Indian J Chest Dis Allied Sci. 2006;48(1):13–22.Google Scholar
  13. 13.
    Diette GB, Fuhlbrigge AL, Ramey AF, et al. Asthma severity in patients initiating controller monotherapy versus combination therapy. J Asthma. 2011;48:304–10.CrossRefGoogle Scholar
  14. 14.
    Rajanandh MG, Nageswari AD, Ilango K. Development and validation of knowledge, attitude, practice questionnaire for asthma and assessment of impact of patient education on asthma patients. Int J Pharm Pharm Sci. 2014;6:309–11.Google Scholar
  15. 15.
    Ramsay CF, Pearson D, Mildenhall S, et al. Oral montelukast in acute asthma excerbations: a randomized double-blind, placebo controlled trial. Thorax. 2011;66:7–11.CrossRefGoogle Scholar
  16. 16.
    Cowie RL, Underwood MF, Field SK. Inhaled corticosteroid therapy does not control asthma. Can Respir J. 2004;11:555–8.CrossRefGoogle Scholar
  17. 17.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1–12.CrossRefGoogle Scholar
  18. 18.
    Lim S, Jataksson A, Gordon D, et al. Comparison of high dose inhaled corticosteroids, low dose inhaled inhaled corticosteroids plus low dose theophylline and low dose inhaled steroids alone in chronic asthma in general practice. Thorax. 2000;55:837–41.CrossRefGoogle Scholar
  19. 19.
    Yurdakul AS, Calisir HC, Tunctan B, et al. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respir Med. 2002;96(2):322–39.CrossRefGoogle Scholar
  20. 20.
    Price DB, Hemandez D, Magyar P, et al. Clinical outcomes with montelukast as a partner agent to corticosteroid therapy (COMPACT) international study group: randomized controlled trial of montelukast plus inhaled budesonide versus double dose of inhaled corticosteroids in adult patients with asthma. Thorax. 2003;58:211–6.CrossRefGoogle Scholar
  21. 21.
    Wang Y, Wang CZ, Lin KX, et al. Comparison of inhaled corticosteroids combined with theophylline and double dose inhaled corticosteroids in moderate to severe asthma. Respirology. 2005;10:189–95.CrossRefGoogle Scholar
  22. 22.
    Shah AR, Sharples LD, Solanki RN, et al. Double-blind, randomized controlled trial assessing controller medications in asthma. Respiration. 2006;73:449–56.CrossRefGoogle Scholar
  23. 23.
    Rajanandh MG, Nageswari AD, Ilango K. Pulmonary function assessment in mild to moderate persistant asthma patients receiving montelukast, tiotropium with budesonide: a randomized controlled study. Clin Ther. 2014;36(4):526–33.CrossRefGoogle Scholar
  24. 24.
    Rajanandh MG, Nageswari AD, Ilango K. Effect of two controller medications with inhaled corticosteroid in mild to moderate persistent asthma patients. J Med Sci. 2014;14:81–6.CrossRefGoogle Scholar
  25. 25.
    Rajanandh MG, Nageswari AD, Ilango K. Assessment of various second-line medications in addition to inhaled corticosteroid in asthmatic patients: a randomized controlled trial. Clin Exp Pharmacol Physiol. 2014;41(7):509–13.CrossRefGoogle Scholar
  26. 26.
    Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clin Ther. 2015;37(2):418–26.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Muhasaparur Ganesan Rajanandh
    • 1
    Email author
  • Sivaguru Paramesh Ahalya
    • 1
  • Rajendran Anjali
    • 1
  • Arunagiri Abirami
    • 1
  • Jamindar Ganesh Bhuvaneswari
    • 1
  1. 1.Department of Pharmacy Practice, Faculty of PharmacySri Ramachandra Institute of Higher Education and Research, Deemed to be UniversityChennaiIndia

Personalised recommendations